Skip to content
Screener

Penumbra PEN Stock-Based Comp

Stock-Based Comp at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$458M+11.7%
Stryker logo
StrykerSYK
$87M+3.6%
AngioDynamics logo
AngioDynamicsANGO
$3.92M+139%
Medtronic logo
MedtronicMDT
$95M+6.7%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$8.96M-1.3%
TFX
TeleflexTFX
$5.44M-3.8%

Other financials

Income statement

See full
Revenue$374.8M+15.6%
Gross profit$253.4M+17.4%
Operating income$38.2M-5.2%
Net income$32.6M-16.9%
EPS (diluted)$0.82-18.0%

Balance sheet

See full
Cash & equivalents$241.3M-35.8%
Total debt$216.2M-2.0%
Total equity$1.5B+21.5%
Total assets$1.9B+19.2%

Cash flow

See full
Operating cash flow$87.0M+77.6%
CapEx$13.7M+1.5%
Free cash flow$73.3M+106%

Valuation

See full
Market cap$12.73B+36.0%
Enterprise value$12.71B+38.7%
P/E74.4×+11.1×
P/S8.8×+1.4×

Profitability

See full
Gross margin67.4%+3.7pp
Operating margin12.9%+9.8pp
Net margin11.8%+8.4pp
FCF margin14.6%+2.5pp

Returns & leverage

See full
Return on equity12.7%+9.2pp
Debt / equity0.1×0.0×
Current ratio-0.3×

Where this comes from

Reported directly by Penumbra in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: Penumbra’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:45 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001321732-26-000019
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Net income$32,584$39,223
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization4,5745,015
Stock-based compensation14,64513,785
Inventory write-downs1,6342,485
Deferred taxes(727)(1,998)
Other(1,211)452
Changes in operating assets and liabilities:

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Penumbra's stock-based comp?
Penumbra (PEN) reported stock-based comp of $14.65M in Q1 2026.
How has Penumbra's stock-based comp changed year-over-year?
Penumbra's stock-based comp increased by 6.2% year-over-year, from $13.79M to $14.65M.
What is the long-term trend for Penumbra's stock-based comp?
Over 4 years (2021 to 2025), Penumbra's stock-based comp has grown at a -2.6% compound annual growth rate (CAGR), from $65.76M to $59.21M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about Penumbra's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude